CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or i...
Phase 1, Phase 2
Pittsburgh, Pennsylvania, United States and 26 other locations
This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...
Phase 3
Pittsburgh, Pennsylvania, United States and 160 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomiz...
Phase 2
Pittsburgh, Pennsylvania, United States and 43 other locations
will be evaluated in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has ...
Phase 1, Phase 2
Pittsburgh, Pennsylvania, United States and 55 other locations
in combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who ar...
Phase 1, Phase 2
Pittsburgh, Pennsylvania, United States and 33 other locations
This phase 2 study aims to confirm the efficacy seen in the prior phase 1 trial, and further contribute to this effort through the collection of leukemia...
Phase 2
Pittsburgh, Pennsylvania, United States and 1 other location
Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible f...
Phase 3
Pittsburgh, Pennsylvania, United States and 171 other locations
The purpose of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute ...
Phase 1
Pittsburgh, Pennsylvania, United States and 22 other locations
combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute...
Phase 3
Pittsburgh, Pennsylvania, United States and 275 other locations
monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodyspla...
Phase 1, Phase 2
Pittsburgh, Pennsylvania, United States and 50 other locations
Clinical trials
Research sites
Resources
Legal